|
CCDC55 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6251444634463E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.2129854332652E-13 |
| Normal-vs-Stage2 |
8.31669999534768E-09 |
| Normal-vs-Stage3 |
1.84210424691855E-11 |
| Normal-vs-Stage4 |
3.96904731303493E-12 |
| Stage1-vs-Stage2 |
7.091000E-01 |
| Stage1-vs-Stage3 |
1.613020E-01 |
| Stage1-vs-Stage4 |
6.439900E-02 |
| Stage2-vs-Stage3 |
5.501000E-01 |
| Stage2-vs-Stage4 |
3.103600E-01 |
| Stage3-vs-Stage4 |
6.870800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.99520433297585E-15 |
| Normal-vs-AfricanAmerican |
4.358200E-04 |
| Normal-vs-Asian |
7.11219999560697E-08 |
| Caucasian-vs-AfricanAmerican |
1.604990E-01 |
| Caucasian-vs-Asian |
5.649400E-01 |
| AfricanAmerican-vs-Asian |
3.915000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.32827124036339E-15 |
| Normal-vs-Female |
1.71207492627445E-12 |
| Male-vs-Female |
2.290400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.33104679792496E-12 |
| Normal-vs-Age(41-60Yrs) |
2.22033502694785E-12 |
| Normal-vs-Age(61-80Yrs) |
2.93698398934339E-12 |
| Normal-vs-Age(81-100Yrs) |
2.36859999999117E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.916600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.964030E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.769410E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.201600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.426000E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.961400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.102900E-03 |
| Classical-VS-Follicular |
3.587800E-01 |
| Classical-VS-Other |
3.582200E-01 |
| Classical-VS-Normal |
2.00250926951639E-12 |
| Tall-VS-Follicular |
1.394240E-01 |
| Tall-VS-Other |
8.061400E-01 |
| Tall-VS-Normal |
3.30929728065144E-11 |
| Follicular-VS-Other |
6.446600E-01 |
| Follicular-VS-Normal |
3.4856000308281E-09 |
| Other-VS-Normal |
8.844300E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.99440505513849E-15 |
| Normal-vs-N1 |
1.41989999757897E-08 |
| N0-vs-N1 |
8.868000E-01 |
|
|
